


814
A50
5-6-02
RECEIVED

TECH CENTER 1600/2900

MAY 03 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2852-C

ANDERSON and GALIBERT

Confirmation No. 1630

Serial No: 09/688,459

Group Art Unit: 1646

Filed: October 13, 2000

Examiner: E. Lazar Wesley

For: ISOLATED DNA MOLECULE ENCODING RANK LIGAND

Commissioner for Patents
Washington, DC 20231

AMENDMENT AND RESPONSE

In response to the Office Action mailed December 18, 2001, please enter the following amendments into the application:

In the Specification:

At page 1, please delete the first paragraph following the heading "CROSS-REFERENCE TO RELATED PATENT APPLICATIONS" and substitute therefor the following paragraph:

B1
-- This application is a divisional of U.S. patent application 08/995,659, filed December 22, 1997, now U.S. patent 6,242,213, which claims benefit of priority under 35 U.S.C. §119(e) from USSN 60/064,671, filed October 14, 1997, USSN 60/077,181, filed March 7, 1997, and USSN 60/059,978, filed December 23, 1996. --

At pages 2-3, please delete the paragraph located at page 2, line 35 to page 3, line 3.

At page 3, please delete the paragraph at lines 4-8 and substitute therefor the following paragraph:

B2
-- Figure 2 demonstrates that RANKL enhances DC allo-stimulatory capacity. Allogeneic T cells were incubated with varying numbers of irradiated DC cultured as described in Example 13. The cultures were pulsed with [³H]-thymidine and the cells harvested onto glass fiber sheets for counting. Values represent the ± standard deviation (SD) of triplicate cultures. --

At page 5, please delete in its entirety the paragraph at lines 10-19, which begins with "Soluble RANKL comprises a signal . . ." and substitute therefor the following paragraph:

05/02/2002 GGEBREGI 00000089 090089 09688459

04 FC:115

110.00 CH

05/02/2002 GGEBREGI 00000089 090089 09688459

01 FC:103

414.00 CH

02 FC:102

252.00 CH